What is Laquinimod?

Category: Others

false

Laquinimod is an immunomodulator currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 2

Commonly reported side effects and conditions associated with Laquinimod

Side effect Patients

Dosages

Based on patients currently using Laquinimod

Dosage Patients
0.6 mg daily 1

Why patients stopped taking Laquinimod

Multiple reasons could be selected

Reason Patients
Did not seem to work 1
Other 1
See all 2 patients who've stopped using Laquinimod

Duration

Currently using Laquinimod

Duration Patients
5 - 10 years 1

Stopped using Laquinimod

Duration Patients
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 2
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 0

What people switch to and from

Patients started using Laquinimod after stopping:

Treatment Patients
Natalizumab (Tysabri) 1

Patients stopped using Laquinimod and switched to:

Treatment Patients
Natalizumab (Tysabri) 1
Last updated:
There are no evaluations for Laquinimod.